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The transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) plays a complex role during the replication of primate lentiviruses. On the
one hand, NF-κB is essential for induction of efficient proviral gene expression. On
the other hand, this transcription factor contributes to the innate immune response
and induces expression of numerous cellular antiviral genes. Recent data suggest that
primate lentiviruses cope with this challenge by boosting NF-κB activity early during the
replication cycle to initiate Tat-driven viral transcription and suppressing it at later stages
to minimize antiviral gene expression. Human and simian immunodeficiency viruses
(HIV and SIV, respectively) initially exploit their accessory Nef protein to increase the
responsiveness of infected CD4+ T cells to stimulation. Increased NF-κB activity initiates
Tat expression and productive replication. These events happen quickly after infection
since Nef is rapidly expressed at high levels. Later during infection, Nef proteins of HIV-2
and most SIVs exert a very different effect: by down-modulating the CD3 receptor, an
essential factor for T cell receptor (TCR) signaling, they prevent stimulation of CD4+ T
cells via antigen-presenting cells and hence suppress further induction of NF-κB and an
effective antiviral immune response. Efficient LTR-driven viral transcription is maintained
because it is largely independent of NF-κB in the presence of Tat. In contrast, human
immunodeficiency virus type 1 (HIV-1) and its simian precursors have lost the CD3
down-modulation function of Nef and use the late viral protein U (Vpu) to inhibit NF-κB
activity by suppressing its nuclear translocation. In this review, we discuss how HIV-1
and other primate lentiviruses might balance viral and antiviral gene expression through
a tight temporal regulation of NF-κB activity throughout their replication cycle.
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INTRODUCTION
To allow efficient viral gene expression, replication, and spread, viral pathogens need to exploit
the cellular transcriptional machinery. In some cases, they hijack exactly those transcription
factors that are activated by the host response to infection to initiate antiviral immune
responses. The interaction of human immunodeficiency virus type 1 (HIV-1) and related simian
immunodeficiency viruses (SIVs) with the NF-κB (nuclear factor kappa-light-chain-enhancer of
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activated B cells) family of transcription factors provides a
prime example for the hostile takeover of a key mediator of
the immune response by viral pathogens (Hiscott et al., 2001;
Chan and Greene, 2012). NF-κB is ubiquitously expressed and
its dysregulation is associated with many pathologies including
cancer, cardiovascular, pulmonary, and inflammatory diseases
(Panday et al., 2016). NF-κB can be induced by multiple
stimuli and regulates the expression of cellular genes involved
in numerous processes, such as cell proliferation, DNA repair
and cell differentiation or survival (Ghosh and Hayden, 2012;
Napetschnig and Wu, 2013). Furthermore, NF-κB plays a
key role in inflammation and the induction of innate and
adaptive immune responses, including expression of interferon-
stimulated genes (ISGs) representing a first line of defense against
viral pathogens (Hayden et al., 2006; Vallabhapurapu and Karin,
2009; Pfeffer, 2011).
NF-κB has a complex role in HIV-1 replication and
pathogenesis. ISGs exert numerous effector functions and
may target almost every step of the retroviral replication cycle
(Kluge et al., 2015; Colomer-Lluch et al., 2016). Thus, their
induction by NF-κB transcription factors might have beneficial
effects for the host by suppressing HIV-1 replication. However,
induction of interferon and other cytokines also contributes
to HIV-1-induced chronic and systemic inflammation that
drives progression to AIDS. Thus, whether induction of
interferon responses is beneficial or harmful in HIV-1
infection is a matter of debate (Doyle et al., 2015; Utay
and Douek, 2016). Importantly, NF-κB is also critical for
potent viral gene expression from the HIV-1 long terminal
repeat (LTR) promoter that typically contains two adjacent
NF-κB binding sites in its main enhancer region (Chan and
Greene, 2012). Combinations of stimulatory drugs including
NF-κB inducing agents, such as prostratin, are currently
examined for their ability to activate the latent reservoirs of
HIV-1 to render them susceptible for elimination (Jiang and
Dandekar, 2015; Cary et al., 2016). Thus, NF-κB presents
a target for therapeutic intervention both by suppressing
its activation to prevent harmful inflammation (Chan and
Greene, 2012) or by activating this transcription factor to
stimulate the latent reservoirs of HIV-1 (Jiang and Dandekar,
2015).
Numerous studies have examined the effects of HIV-1
infection on NF-κB activity (reviewed in Chan and Greene,
2012). Altogether, the results were puzzling and frequently
controversial. Recent evidence suggests that HIV-1 and other
primate lentiviruses may have differential effects during the early
and late stages of their replication cycle and tightly regulate
NF-κB activity (Sauter et al., 2015). In the present review, we
first briefly describe some basic aspects of NF-κB signaling
and its interaction with the LTR promoter of HIV-1 and other
primate lentiviruses. Subsequently, we discuss how these viruses
might modulate NF-κB activity throughout their replication cycle
to ensure efficient viral gene expression while minimizing the
expression of antiviral genes.
BASIC MECHANISMS OF NF-κB
SIGNALING
NF-κB was initially discovered in the laboratory of David
Baltimore because of its ability to bind the enhancer region
of the immunoglobulin κ light-chain- in B cells (Sen and
Baltimore, 1986). Since then, five mammalian NF-κB members,
i.e., NF-κB1 (p50/p105), NF-κB2 (p52/p100), RelA (p65), RelB
and c-Rel, have been identified (Nabel and Verma, 1993). All
of them share a highly conserved N-terminal Rel homology
domain that is critical for dimerization and DNA binding,
while three of them (p65, RelB, and c-Rel) contain an
additional C-terminal transactivation domain. The remaining
two factors (NF-κB1 and NF-κB2) are synthesized as large
inactive precursors (p105 and p100) that need to undergo
proteasomal degradation of their ankyrin repeat containing
C-terminal region to generate the mature p50 and p52 NF-
κB subunits, respectively (Karin and Ben-Neriah, 2000). DNA
binding and transcriptional regulation requires dimerization of
two subunits, with p50/p65 dimers being the most abundant
active form. Many other dimer combinations were observed but
not all of them act as transcriptional activators; e.g., p50/p50 and
p52/p52 homodimers were reported to suppress NF-κB mediated
transcription as they lack a transactivation domain (Zhong et al.,
2002).
In unstimulated cells, NF-κB dimers are bound to so-called
inhibitors of κB (IκBs) containing ankyrin repeats that mask
nuclear localization signals (NLS) and thereby keep the NF-
κB proteins sequestered in the cytoplasm. The p105 and p100
precursors also contain ankyrin repeats in their C-terminal parts.
Thus, they inhibit NF-κB activity and may also be classified as IκB
proteins. A multitude of stimuli including viral antigens, immune
cells, mitogens and cytokines, specific cell surface receptors,
such as the T cell receptor (TCR)-CD3 complex, IFN receptors,
the interleukin 1 receptor (IL-1R), Toll-like receptors (TLRs),
or tumor necrosis factor (TNF) receptors induce degradation
of IκB proteins (Vallabhapurapu and Karin, 2009). The main
mechanism (canonical pathway) involves activation of IκB kinase
(IKK), a heterodimer composed of the catalytic IKKα and
IKKβ subunits and a regulatory factor termed NEMO (NF-κB
essential modulator), and subsequent phosphorylation of serine
residues in IκB regulatory domains allowing its ubiquitination
and proteasomal degradation (Figure 1). Degradation of IκB
allows exposure of the NLS and thus entry of the NF-κB complex
into the nucleus for DNA binding and transcriptional induction
of genes containing the appropriate binding sites within their
promoter regions. As outlined below, NF-κB activation induces
immune responses as well as HIV-1 proviral gene expression.
Notably, NF-κB also induces expression of IκBα, resulting in a
negative autoregulatory feedback loop and thus oscillating levels
of NF-κB activity (Nelson et al., 2004). More in depth reviews of
NF-κB signaling and its regulation are provided by Oeckinghaus
and Ghosh (2009), Skaug et al. (2009) and Vallabhapurapu and
Karin (2009).
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FIGURE 1 | Activation of the canonical NF-κB pathway. Simplified schematic presentation of NF-κB activation by different cellular receptors. Binding of the
TCR-CD3 complex to antigens presented by MHC molecules induces LCK-dependent phosphorylation of ITAMs in the cytoplasmic tail of CD3. This in turn recruits
ZAP70, which induces a signal cascade involving activation of PLCγ1 and PKCθ. Alternatively, PKCθ can also be activated via a signal cascade including PI3K
following binding of the TCR costimulatory factor CD28 to a B7 ligand. PKCθ subsequently activates the CBM complex consisting of CARD11, BCL10 and MALT1,
which activates TAK1 in a TRAF6 dependent manner. Ligand binding to TLRs or TNF receptors also induces TAK1 activation in a TRAF6- or TRAF2-dependent
manner, respectively. In humans (and to a much lesser extent in chimpanzees), the cellular restriction factor tetherin also acquired the ability to activate NF-κB. Upon
tethering of newly formed viral particles and clustering of tetherin dimers, the cytoplasmic tail of tetherin becomes phosphorylated at a conserved YxY motif by a
Scr-family kinase in a RICH2-dependent manner, recruiting SYK, which initiates a signaling cascade involving TRAF2 and/or TRAF6 resulting in the activation of
TAK1. TAK1 subsequently phosphorylates IKKβ at two serine residues in the activation loop to activate IKK. Furthermore, TRAFs activate NEMO by
poly-ubiquitination, followed by activation of the catalytic subunits IKKα and IKKβ. Subsequently, IκB is phosphorylated and poly-ubiquitinated by the SCF/β-TrCP
complex, which results in its proteasomal degradation, thereby releasing p50/p65 heterodimers, which translocate to the nucleus where they bind to specific κB
binding sites and initiate NF-κB-dependent gene expression.
ROLE OF NF-κB IN IMMUNITY AND
INFLAMMATION
It is well established that NF-κB transcription factors regulate
many genes involved in immune and inflammatory responses
(reviewed in Vallabhapurapu and Karin, 2009). Upon pathogen
recognition, a variety of cellular pattern recognition receptors
(PRRs), including cGAS [Cyclic-GMP-AMP (cGAMP) synthase],
STING (stimulator of interferon genes), IFI16 (interferon
γ-inducible protein 16), RIG-I-like helicases, NOD-like receptors
(NLRs) and TLRs may activate the NF-κB pathway. Thus,
NF-κB signaling is induced by multiple stimuli, including
pathogen associated molecular patterns (PAMPs) as well as
proinflammatory cytokines, e.g., tumor necrosis factor-α (TNF-
α) and interleukin-1. Ligand binding to TLRs induces several
downstream effectors and results in the formation of signaling
complexes activating the IKK complex (Figure 1). Ubiquitination
of TNF-receptor-associated factors (TRAF) and NEMO facilitates
activation of the catalytic IKKβ subunit resulting in the
phosphorylation and proteasomal degradation of IκB and
consequently nuclear translocation of active NF-κB dimers
(Skaug et al., 2009). Similarly, signaling via members of the
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TNF receptor superfamily ultimately leads to activation of the
IKK complex, following recruitment of various adaptor proteins
and stimulation of TGF-β-activated kinase 1 (TAK1; Wang and
Baldwin, 1998). Furthermore, some activated TNFR superfamily
members may induce accumulation of mitogen-activated protein
kinase 14 (MAP3K14 or NF-κB-inducing kinase, NIK) that
activates IKKα to induce processing of p100 and thus activation
of e.g., RelB/p52 heterodimers to mediate expression of NF-κB-
responsive genes via the non-canonical pathway. This pathway is
slower than the canonical NF-κB signaling pathway and can also
be activated via the CD40 ligand (CD40L), receptor activator of
NF-κB ligand (RANKL) or lymphotoxin β (Cildir et al., 2016).
Following activation, RelB/p52 heterodimers translocate to the
nucleus for target gene activation.
NF-κB is not only a key factor in the induction of effective
innate immune responses but also plays an important role
in adaptive immunity. For example, ligand binding to the
TCR complex induces recruitment of LCK tyrosine kinase that
phosphorylates the ITAMs of the CD3 ζ chains (Figure 1).
Subsequent recruitment of ZAP70 mediates activation of a
signaling pathway involving PLCγ, protein kinase C (PKC)
family members, the CARD11-BCL10-MALT1 (CBM) complex,
TRAF6, and ultimately TAK1, inducing NF-κB activity by
phosphorylation and activation of IKKs (Cheng et al., 2011;
Paul and Schaefer, 2013). NF-κB activation is further enhanced
by costimulation via CD28, which triggers distinct signaling
cascades involving PI3K and PDK1 (Boomer and Green, 2010).
Thus, the signaling pathways induced by CD3/CD28-mediated
stimulation of T cells upon interaction with antigen-presenting
cells (APCs) allow NF-κB to enter the nucleus to upregulate
expression of cytokines and antimicrobial effectors as well
as genes involved in T cell survival, proliferation, and
differentiation. Consequently, regulation of NF-κB activity plays
a key role in innate and adaptive immune function and the
defense against bacterial and viral pathogens. In agreement
with this important role in inflammatory gene expression,
chronic activation of NF-κB signaling is observed in a variety
of inflammatory diseases including arthritis, sepsis, gastritis,
asthma, atherosclerosis, and inflammatory bowel disease (Panday
et al., 2016).
ROLE OF NF-κB IN PRIMATE
LENTIVIRAL TRANSCRIPTION
It is long known that HIV-1 transcription can be stimulated by
activation of the canonical NF-κB pathway (Nabel and Baltimore,
1987; Tong-Starksen et al., 1987). NF-κB binding sites are found
in the enhancer region of all primate lentiviral LTRs, although
their numbers may vary between different subtypes of HIV-1
group M and various groups of SIV and HIV. Most subtypes of
pandemic HIV-1 group M strains (A, B, D, F, G, H, J, and K) and
some SIVs contain two NF-κB binding sites located –104 to –
80 bp upstream of the transcriptional start site within the 5′LTR
(Figure 2). In contrast, the second human immunodeficiency
virus (HIV-2), subtype A/E recombinants of HIV-1 group M
and several SIV lineages contain just a single NF-κB binding
site. Finally, subtype C strains, which account for almost 50%
FIGURE 2 | Role of κB binding sites in primate lentiviral LTR-mediated transcription. (A) Localization of κB binding sites in primate lentiviral LTRs. NF-κB
binding allows recruitment of p300 to initiate chromatin acetylation and to render the LTR better accessible for RNAPII. NF-κB also recruits P-TEFb, which binds to
the CTD of RNAPII and strongly enhances its processivity. De-phosphorylation of the CTD by an OA-sensitive phosphatase terminates the elongation, resulting in the
production of short TAR-containing transcripts. (B) In the presence of the viral Tat protein, transcription of proviral DNA is maintained independently of NF-κB. Tat
binds to the short hairpin loop of TAR and recruits P-TEFb to the RNAPII, thereby allowing efficient elongation and generation of full-length viral transcripts.
Frontiers in Microbiology | www.frontiersin.org 4 February 2017 | Volume 8 | Article 198
fmicb-08-00198 February 10, 2017 Time: 17:56 # 5
Heusinger and Kirchhoff Modulation of NF-κB Activity by HIV and SIV
of HIV-1 infections worldwide, typically contain three binding
sites for NF-κB in their enhancer region (Bachu et al., 2012).
LTR-mediated transcription is initiated by binding of p50/p65
heterodimers or other members of the NF-κB transcription factor
family that recruit p300 to promote acetylation of LTR chromatin
and allow access for RNA polymerase II (RNAPII; Figure 2A).
NF-κB binding also promotes transcriptional elongation by
recruiting the positive transcription elongation factor b (P-
TEFb) complex and the transcription factor TFIIH to the
carboxyl domain (CTD) of RNAPII, allowing its phosphorylation
that results in increased processivity of this enzyme (Barboric
et al., 2001). However, this effect is transient since an okadaic
acid (OA)-sensitive phosphatase dephosphorylates the CTD of
RNAPII to prevent P-TEFb interaction. Thus, short transcripts
terminated shortly after the trans-activation response (TAR)
RNA element predominate at the early stage. Accumulation of
the viral Tat protein that binds to TAR and recruits P-TEFb
allows the virus to overcome this bottleneck by allowing
hyper-phosphorylation of RNAPII and potent transcriptional
elongation and the generation of full-length viral transcripts
(Williams et al., 2007) (Figure 2B).
Typically, mutation of the NF-κB binding sites in HIV-1 LTRs
will prevent efficient proviral transcription. However, one case
of a replication-competent pathogenic HIV-1 strain lacking NF-
κB binding sites has been reported (Zhang et al., 1997). This
unusual HIV-1 strain contained duplications in the TCF-1alpha
region that may have compensatory effects. Thus, NF-κB binding
sites are important but not essential for HIV-1 replication or
pathogenicity in vivo. Since NF-κB activation stimulates HIV-1
transcription, it is also targeted in approaches aiming to eliminate
the latent viral reservoirs. Induction of NF-κB activity by T cell
activation or treatment with phorbol esters, such as prostratin,
potently enhance viral gene expression (Coudronniere et al.,
2000; Williams et al., 2004). However, since NF-κB transcription
factors are involved in numerous physiological and pathological
processes, their induction is prone to adverse effects. Notably,
some members of the NF-κB transcription factor family may
also promote HIV-1 latency, i.e., it has been reported that in
unstimulated T cells, p50 homodimers occupy the NF-κB sites in
the proviral LTR to recruit HDAC1, thereby promoting histone
hypo-acetylation and hence chromatin condensation rendering
the viral LTR poorly accessible to RNAPII binding (Williams
et al., 2006).
INDUCTION OF NF-κB SIGNALING BY
VIRAL IMMUNE SENSING AND DNA
DAMAGE RESPONSES
HIV-1 infection modulates NF-κB signaling by multiple
mechanisms. As outlined above, sensing of viral PAMPs by
PRRs activates NF-κB to induce an antiviral immune response.
HIV-1 sensing is not fully understood as the virus has evolved
effective evasion mechanisms. For example, recent evidence
suggests that the viral capsid stays largely intact until it docks
to the nucleopore (Arhel et al., 2007; Lelek et al., 2012; Dharan
et al., 2016) and that it recruits cellular factors, such as PSF6 and
cyclophilins, to prevent innate immune activation (Rasaiyaah
et al., 2013). Nonetheless, it has become clear that a variety of
viral components may trigger immune responses. Viral RNA or
DNA intermediates of the reverse transcription (RT) process can
be sensed by cytosolic receptors, such as cGAS, IFI16, PQBP1
and RIG-I, particularly under suboptimal conditions for efficient
RT (Jakobsen et al., 2015; Sauter and Kirchhoff, 2016). Moreover,
antiretroviral restriction factors may also act as immune sensors
(Hotter et al., 2013). For example, TRIM5α induces untimely
uncoating of the viral capsid and may also act as an activator of
the TAK1 kinase complex to stimulate AP-1 and NF-κB signaling
(Pertel et al., 2011). Similarly, trapping of HIV-1 particles by
the host restriction factor tetherin induces phosphorylation of
tyrosine residues in its cytoplasmic tail to mediate recruitment of
SYK tyrosine kinase and TRAF2 and/or 6 to activate TAK1 and
consequently NF-κB-dependent immune responses (Galão et al.,
2012, 2014; Tokarev et al., 2013) (Figure 1). Interestingly, this
sensing function of tetherin seems to have an evolutionary recent
origin and is only observed for the human and (to a much lesser
extent) chimpanzee orthologs (Galão et al., 2012), whereas the
ability of tetherin to block virion release has a very ancient origin
(Heusinger et al., 2015; Blanco-Melo et al., 2016). Finally, HIV-1
infection induces DNA damage responses since the generation
of linear viral RNA/DNA and DNA species, non-integrated
circular forms of viral DNA and a double-stand break in the
host-genome are inevitable concomitants of the viral replication
cycle. DNA damage signaling may activate ATM and mediate
phosphorylation and ubiquitination of NEMO to induce IKK
and consequently NF-κB activation (Miyamoto, 2011; McCool
and Miyamoto, 2012).
ACTIVATION OF NF-κB TO INITIATE
EARLY VIRAL GENE TRANSCRIPTION
HIV-1 not only affects NF-κB activation by triggering immune
sensors and inducing DNA damage responses but may also
use some of its gene products to manipulate this transcription
factor to promote efficient viral gene expression. Many studies
investigated the effect of HIV-1 on NF-κB activation but the
initial results were often contradictory. One possible reason
for this is that NF-κB signaling plays a complex role in the
viral replication cycle and that effects may depend on the cell
type and state of activation, as well as the stimuli and HIV-1
strains or proteins used in the respective studies. Furthermore,
accumulating evidence suggests that the HIV-1 Nef and Tat
proteins that are expressed at high levels immediately after
initiation of proviral transcription enhance and late viral gene
products, such as Vpu, suppress NF-κB activation (Roux et al.,
2000; Akari et al., 2001; Bour et al., 2001; Varin et al., 2005;
Herbein et al., 2008; Mangino et al., 2011; Fiume et al., 2012; Liu
et al., 2013). It has been reported that Tat interacts with IκBα and
the p65 subunit of NF-κB to prevent binding of the repressor
to the NF-κB complex while promoting p65 binding to DNA
(Fiume et al., 2012). It has also been shown that the cytoplasmic
domain of the HIV-1 envelope glycoprotein (Env) gp41 interacts
with TAK1 to induce NF-κB activation (Postler and Desrosiers,
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2012). Whether this mechanism is effective during the earliest
stage of infection, i.e., induced by virion fusion with the plasma
cell membrane of the target cell, or requires higher quantities of
Env achieved during later stages of the replication cycle remains
to be determined. Finally, a variety of studies reported that Vpr
modulates NF-κB signaling in various cell types. However, the
effects are controversial and both stimulatory and inhibitory
effects of Vpr have been described (Kogan et al., 2013; Liu
et al., 2013, 2014; Liang et al., 2015). Thus, the effects of
virion-associated and de novo synthesized Vpr in primary HIV-1
infected T cells need to be further investigated.
The accessory viral Nef protein does not induce NF-κB activity
on its own but boosts the responsiveness of HIV-1 infected
cells to stimulation (Alexander et al., 1997; Simmons et al.,
2001; Fenard et al., 2005) (Figure 3A). Nef-mediated activation
of NF-κB, nuclear factor of activated T cells (NFAT), IL-2
and LTR stimulation following TCR-CD3/CD28 costimulation
seems to require association with lipid rafts (Schrager and
Marsh, 1999; Fortin et al., 2004; Kumar et al., 2016) and
may depend on the state of activation of infected T cells
(Baur et al., 1994). Interactions of HIV-1 Nef with the CD3
ζ chain (Xu et al., 1999) and downstream effectors of TCR
signaling, such as the tyrosine kinase LCK (Baur et al., 1997),
serine/threonine p21-activating kinases (Sawai et al., 1994),
the DOCK2-ELMO1 complex (Janardhan et al., 2004) and
ERK/MAP kinases (Schrager et al., 2002) have been reported.
Thus, Nef might affect the catalytic activity of different kinases,
induce cytoskeletal changes, and activate a variety of signaling
pathways. The relative contribution of these activities and
interactions to Nef-mediated enhancement of T cell activation is
largely unclear. In either case, Nef promotes nuclear translocation
of NF-κB and other transcription factors, such as AP1 and
NFAT and activates the viral promoter to induce Tat expression
and hence productive viral replication (Kinoshita et al., 1998).
Notably, Nef may exert its multiple functions rapidly after viral
entry since it is expressed at high levels early during the viral
replication cycle and possibly even before proviral integration
(Sloan et al., 2011).
LATE INHIBITION OF NF-κB SIGNALING
BY HIV-1 AND ITS VPU CONTAINING SIV
COUNTERPARTS
While Nef-mediated enhancement of NF-κB activity may be
important to initiate proviral transcription, it is less critical after
accumulation of the viral Tat protein and may even become
detrimental to HIV-1 replication because of the induction
of antiviral gene expression. Thus, HIV-1 and other primate
lentiviruses might tightly regulate NF-κB activity throughout
their replication cycle to allow proviral transcription while
minimizing antiviral gene expression. Recent studies show that
the accessory viral protein U (Vpu) potently suppresses NF-
κB activity during later stages of the viral replication cycle
(Figure 3B) (Akari et al., 2001; Bour et al., 2001; Sauter et al.,
2015). A vpu gene was most likely acquired by the precursor
of SIVs infecting Cercopithecus monkeys with subsequent cross-
species transmissions and recombination events giving rise to
other vpu containing primate lentiviruses (Bailes et al., 2003;
Takeuchi et al., 2015). Thus, vpu is found in HIV-1, its
chimpanzee and gorilla precursors, SIVcpz and SIVgor, and
in SIVgsn, SIVmus, SIVmon, and SIVden, infecting greater
spot-nosed, mustached, mona, and Dent’s mona monkeys,
respectively (Kirchhoff, 2009). The Vpu proteins of pandemic
HIV-1 group M strains counteract tetherin-mediated activation
of NF-κB-dependent antiviral immune responses (Cocka and
Bates, 2012; Galão et al., 2012, 2014; Tokarev et al., 2013).
This is expected since the Vpus of HIV-1 group M and SIVs
infecting several Cercopithecus species are potent antagonists of
tetherin-mediated inhibition of virion release. More surprisingly,
Vpus derived from SIVs infecting chimpanzees and gorillas or
HIV-1 group O strains that use their Nef protein to counteract
tetherin are also potent inhibitors of NF-κB (Sauter et al.,
2015). Indeed, early studies suggested that HIV-1 Vpu prevents
NF-κB activation by inhibiting degradation of IκB through
sequestration of the adaptor protein β-TrCP (Akari et al., 2001;
Bour et al., 2001). More recent data show that the ability
of Vpu to prevent NF-κB activation independently of the
stimulus is conserved between all lineages of SIV and HIV-
1 (except group N) containing this accessory gene and does
not correlate with β-TrCP interaction or tetherin antagonism
(Sauter et al., 2015). In agreement with the results of early
studies (Bour et al., 2001), an intact β-TrCP binding motif
and interaction of Vpu with β-TrCP are essential for highly
effective inhibition of p65 nuclear translocation by primary
Vpu proteins. However, some Vpus failing to recruit β-TrCP
still suppressed NF-κB-dependent gene expression (Sauter et al.,
2015). Thus, the action of Vpu involves stabilization of IκB
and reduced nuclear translocation of p65 but also additional
yet-to-be-defined mechanisms. Importantly, the ability of Vpu
to inhibit NF-κB is dominant over the stimulatory effect of
Nef and associated with reduced induction of IFN and ISGs
in HIV-1 infected T cells (Sauter et al., 2015). Accordingly,
HIV-1 and its closest simian counterparts seem to utilize
Nef to boost NF-κB activation to initiate LTR-driven proviral
transcription. At later stages, when viral gene expression is
ensured by the presence of Tat, Vpu inhibits NF-κB activity to
limit expression of antiviral genes and to attenuate the immune
response.
POTENTIAL SUPPRESSION OF NF-κB
ACTIVATION BY NEF-MEDIATED
DOWN-MODULATION OF TCR-CD3
The ability to inhibit NF-κB activity is highly conserved among
primate lentiviral Vpu proteins (Sauter et al., 2015) suggesting
an important role for viral immune evasion in vivo. As outlined
above, however, vpu genes are only found in HIV-1 and its closest
simian counterparts, raising the question whether the majority
of primate lentiviruses use another mechanism to inhibit NF-
κB during late stages of the replication cycle. It is tempting
to speculate that originally essentially all primate lentiviruses
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FIGURE 3 | Modulation of NF-κB activity by HIV and SIV Nef and Vpu proteins. (A) To initiate early viral gene expression, the viral accessory protein Nef
promotes NF-κB activation by boosting TCR-CD3 mediated T cell activation and other yet to be determined mechanisms. (B) HIV-1 and its closest SIV counterparts
use their Vpu protein to inhibit NF-κB and thus antiviral gene expression during late stages of the replication cycle. Vpu interferes with IκB degradation by
sequestration of β-TrCP and other as-yet-unknown mechanisms. Furthermore, HIV-1 group M and (less effectively) N Vpu proteins counteract the cellular restriction
factor tetherin, which traps budding virions at the cell surface and also acts as NF-κB activating immune sensor in the case of the human ortholog. In the presence
of the viral transactivator Tat, viral transcription is maintained independently of NF-κB activity. (C) HIV-2 and most SIV strains do not contain a vpu gene but express
Nef proteins that efficiently down-modulate CD3 from the cell surface to prevent T cell activation and hence to suppress the induction of NF-κB and other
transcription factors. SIV Nefs also counteract tetherin in their respective host. However, although monkey tetherins restrict virus release they are not known to act as
NF-κB activating immune sensors.
used the CD3 down-modulation function of Nef to suppress
the activity of NF-κB and other transcription factors. This Nef
function is conserved among HIV-2 and most lineages of SIVs
but was entirely lost in the great majority of vpu containing
primate lentiviruses (Schindler et al., 2006). This was most likely
not just coincidence. In fact, phylogenetic and functional analyses
suggest that the CD3 down-modulation function of Nef may
have been lost twice during primate lentiviral evolution when
the virus acquired a vpu gene. The first time after acquisition
of vpu by a precursor of SIVs nowadays found in various
Cercopithecus monkeys and a second time when this virus
recombined with the precursor of SIVrcm from Red-capped
mangabeys in chimpanzees to give rise to SIVcpz, the precursor
of HIV-1 (Kirchhoff, 2010).
It has been suggested that Vpu might diminish the selective
advantage of Nef-mediated CD3 down-modulation because
it counteracts tetherin and potentially other antiviral factors
induced in an inflammatory environment. In fact, lack of CD3
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down-modulation by Nef is associated with higher expression
levels of early (CD69) and late (CD25) activation markers as well
as increased levels of apoptosis, induction of Fas, Fas-L, PD-1,
and CTLA-4 cell surface expression and secretion of interferon
gamma (IFN-γ) in virally infected cultures of peripheral blood
mononuclear cells (Schindler et al., 2006; Schmökel et al., 2011;
Yu et al., 2015). The consequences of the presence of vpu and
the inability of Nef to block TCR-mediated T cell activation,
that distinguish HIV-1 and its simian precursors from other
primate lentiviruses, for viral pathogenicity largely remain a
matter of speculation. While it is evident that host properties
play an important role in the clinical outcome of primate
lentiviral infections (Chahroudi et al., 2012), it is conceivable
that potent inhibition of T cell activation should help to prevent
damagingly high levels of immune activation that drive CD4+
T cell depletion and progression to immunodeficiency (Sodora
et al., 2009). Indeed, inefficient Nef-mediated down-modulation
of CD3 correlates with low numbers of CD4+ T cells in SIVsmm
infected sooty mangabeys (Schindler et al., 2008) and viremic
HIV-2 infected individuals (Khalid et al., 2012). Furthermore,
HIV-1 is more pathogenic than HIV-2 (Nyamweya et al., 2013)
and many SIVs do not cause disease in their natural host
species (Chahroudi et al., 2012), whereas SIVcpz causes AIDS in
chimpanzees (Keele et al., 2009). It is unknown whether other
vpu containing viruses cause disease in the wild. However, the
prevalence of SIVgsn/mus/mon in their natural simian hosts
seems to be much lower (∼1–4%) than of SIVs capable of CD3
down-modulation (often >40%; Heigele et al., 2016). It will be
interesting to further examine whether this is due to differences
in the pathogenic outcome of these infections.
Vpu may allow primate lentiviruses to better cope with the
antiviral immune response not only by antagonizing innate
antiviral factors but also by downregulation of various receptors
involved in the activation of natural killer cells (Sugden et al.,
2016). However, the recent finding that Vpu suppresses NF-κB
activity also suggests a more direct link with the CD3 down-
modulation function of Nef. As described above, signaling via the
TCR-CD3 complex induces a cascade of events ultimately leading
to IKK activation and translocation of NF-κB into the nucleus
for target gene expression (Figure 1). It has been established
that Nef-mediated down-modulation of CD3 potently blocks
the responsiveness of virally infected T cells to TCR-mediated
stimulation (Iafrate et al., 1997; Bell et al., 1998; Khalid et al.,
2012) and prevents the formation of the immunological synapse
between virally infected primary CD4+ T cells and dendritic
cells or macrophages (Arhel et al., 2009). It has been shown
that CD3 down-modulation potently inhibits the induction of
NFAT (Khalid et al., 2012), which also plays an important role
in the immune response (Müller and Rao, 2010). While the
effect on NF-κB activity is less well investigated, preliminary
data clearly indicate that Nef-mediated down-modulation of
CD3 would also block activation of this transcription factor
(Figure 3C). Thus, our current knowledge suggests that most
primate lentiviruses may prevent NF-κB activation by Nef-
mediated down-modulation of CD3, whereas HIV-1 and its
simian precursors utilize Vpu to inhibit NF-κB signaling further
downstream in the cascade. The former mechanism is associated
with a more “resting” phenotype of virally infected T cells
and disrupts their interaction with and responsiveness to other
immune cells (Arhel et al., 2009). The latter may still allow
activation of the infected T cells e.g., by APCs but prevent NF-
κB-dependent antiviral gene expression during later stages of
the viral replication cycle. Notably, most SIVs use their Nef
protein to counteract tetherin (Jia et al., 2009; Sauter et al., 2009;
Zhang et al., 2009). However, this does most likely not affect NF-
κB activity since only the human but not monkey orthologs of
tetherin are known to activate this transcription factor (Galão
et al., 2012). Finally, HIV-2 uses Env to counteract restriction
by human tetherin (Le Tortorec and Neil, 2009) but it has not
been reported whether this mechanism also suppresses induction
of NF-κB activity.
Importantly, the effects of all primate lentiviral Nefs on T cell
activation may differ during the early and late stages of the viral
replication cycle. Perhaps most notably, Nef proteins from HIV-
2 and SIVs that down-modulate CD3 enhance IKKβ-induced
NF-κB activation as efficiently as HIV-1 or SIV Nefs lacking
the CD3 down-modulation function entirely (Sauter et al.,
2015). Thus, primate lentiviral Nef proteins may generally boost
the responsiveness to stimulation during the earliest stage of
infection. While down-modulation of CD3 from the cell surface
by Nef proteins possessing this function is highly effective, it
may take more time than providing an initial boost to NF-
κB activity to initiate viral gene expression and productive
replication. Consequently, early stimulation and late inhibition
of NF-κB may both be achieved by most primate lentiviruses
and be mediated by cooperative Nef and Vpu functions in HIV-
1 and its precursors. Finally, it is noteworthy that even HIV-1
Nef might have differential effects depending on the stage of
infection. It is puzzling that for HIV-1 Nef enhancing (Herbein
et al., 2008; Mangino et al., 2011), inhibitory (Niederman et al.,
1992; Bandres and Ratner, 1994), and no (Yoon and Kim, 1999;
Witte et al., 2008) effects on NF-κB activity have been reported.
In part, these differences may depend on the state of activation
of infected T cells. However, it will also be interesting to further
examine whether the effect of HIV-1 Nef might differ at different
stages of the viral replication cycle. In agreement with this
possibility, it is known that HIV-1 Nefs down-modulate CD28,
an important costimulatory factor of T cell activation, albeit
substantially less effectively than HIV-2 and most SIV Nefs (Bell
et al., 2001; Swigut et al., 2001). Timing adds another degree of
complexity to the already complex role of the multi-functional
Nef protein throughout the viral life cycle and clearly warrants
further examination.
CONCLUSION AND PERSPECTIVES
Numerous studies have investigated how accessory proteins
of HIV and SIV, i.e., Vif, Vpr, Nef, Vpu and/or Vpx,
counteract antiviral restriction factors, such as APOBEC proteins,
tetherin, SAMHD1 and SERINC3/5. Expression of most of
these and other antiviral factors is induced by a very limited
number of transcription factors that are activated upon viral
immune sensing including NF-κB and IRFs. Modulation of
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the induction and activity of these key regulators of innate
and adaptive immunity may have a major benefit for viral
replication but has only recently gained significant scientific
attention. Specifically, recent data provide evidence that primate
lentiviruses tightly regulate the activity of NF-κB to initiate
efficient viral transcription while minimizing the expression of
antiviral genes. As outlined above, the most common mechanism
amongst primate lentiviruses may be initial boosting of NF-
κB activity by Nef and prevention of further stimulation of T
cell activation by potent down-modulation of TCR-CD3. This
strategy seems to be highly successful considering the high
prevalence of these viruses and the benign relationship with their
natural simian hosts. In contrast, HIV-1 and its SIV precursors
seem to use Nef to initially boost and Vpu to later on suppress
NF-κB activation. A variety of Vpu functions that might provide
a selective advance for viral immune evasion and replication
have been reported (Sandberg et al., 2012; Sugden et al., 2016).
Nonetheless, the emergence of a vpu containing subset of primate
lentiviruses is somewhat surprising as they seem to be less
prevalent and potentially more virulent in their natural hosts
than other SIVs. Perhaps they have advantages in specific hosts
as supported by the more efficient spread of HIV-1 in the
human population compared to HIV-2 despite higher virulence.
Notably, a few primate lentiviruses lack both vpu and the CD3
down-modulation function of Nef (Schmökel et al., 2011) and
our preliminary data suggest that they might use yet another
accessory protein (i.e., Vpr) to suppress NF-κB activity during the
late stages of infection.
Altogether, recent evidence suggests that primate lentiviruses
have evolved several sophisticated mechanisms to tightly regulate
the activity of NF-κB and possibly other transcription factors
throughout their replication cycle. The conservation of these
functions supports an important role for viral replication and
immune evasion. Furthermore, modulation of NF-κB activity
is most likely also relevant for viral latency and inflammatory
responses. NF-κB is targeted for the treatment of inflammatory
and proliferative diseases as well as cancer and activation of the
latent reservoirs of HIV-1 (Jiang and Dandekar, 2015; Panday
et al., 2016). Because of its important role in many physiological
processes, however, therapeutic modulation of NF-κB activity is
prone to undesired adverse effects. Nevertheless, further studies
on the mechanisms used by HIV-1 and other primate lentiviruses
to manipulate this central transcription factor may provide
important information on how these viruses establish latency and
induce inflammation and perhaps even on how to prevent this.
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